Provided by Tiger Trade Technology Pte. Ltd.

Ligand Pharmaceuticals

280.18
-6.1100-2.13%
Post-market: 280.180.00000.00%19:30 EDT
Volume:158.24K
Turnover:44.66M
Market Cap:5.59B
PE:28.85
High:286.27
Open:286.27
Low:279.87
Close:286.29
52wk High:326.63
52wk Low:157.52
Shares:19.94M
Float Shares:19.35M
Volume Ratio:0.86
T/O Rate:0.82%
Dividend:- -
Dividend Rate:- -
EPS(TTM):9.71
EPS(LYR):6.13
ROE:21.96%
ROA:3.99%
PB:5.77
PE(LYR):45.71

Loading ...

Ligand price target raised to $250 from $244 at BofA

TIPRANKS
·
Apr 14

Ligand Partner Travere Therapeutics Receives Full FDA Approval for Filspari® (Sparsentan) in Fsgs

THOMSON REUTERS
·
Apr 14

Ligand director John W. Kozarich disposes of shares worth $0.1 million

Reuters
·
Apr 03

Ligand CLO Andrew Reardon disposes of LGND shares worth $0.99 million

Reuters
·
Apr 03

Ligand director John LaMattina disposes of common shares worth $0.43 million

Reuters
·
Apr 01

RBC Raises Price Target on Ligand Pharmaceuticals to $64 From $48, Keeps Outperform Rating

MT Newswires Live
·
Mar 30

Ligand Pharmaceuticals appoints Peter Renehan and Lee Brown as VPs of Investments and Business Development; Lauren Hay moves to VP of Portfolio Strategy and Investments

Reuters
·
Mar 26

Ligand Pharmaceuticals; Director Stephen L. Sabba drops 1,000 common shares worth $207,873

Reuters
·
Mar 25

Ligand Pharmaceuticals Is Maintained at Buy by Citigroup

Dow Jones
·
Mar 24

Ligand Pharmaceuticals Inc : Citigroup Raises Target Price to $276 From $270

THOMSON REUTERS
·
Mar 24

U.S. RESEARCH ROUNDUP-Apogee Therapeutics, Insmed, Sunoco

Reuters
·
Mar 24

Fresh Analyst Coverage Puts Ligand Pharmaceuticals (LGND) Royalty Model And Valuation In The Spotlight

Simply Wall St.
·
Mar 15

Ligand Pharmaceuticals CFO Octavio Espinoza Disposes of Common Shares

Reuters
·
Mar 14

How Bank of America’s Royalty-Focused Coverage At Ligand Pharmaceuticals (LGND) Has Changed Its Investment Story

Simply Wall St.
·
Mar 14

Ligand Pharmaceuticals Down Over 9%, on Pace for Largest Percent Decrease Since January 2022 -- Data Talk

Dow Jones
·
Mar 12

Is It Too Late To Consider Ligand Pharmaceuticals (LGND) After A 105% One-Year Surge?

Simply Wall St.
·
Mar 12

Ligand Pharmaceuticals Is A Low-Risk Way To Bet On Biopharma Growth: Analyst

Benzinga_recent_news
·
Mar 12

BofA Securities Initiates Ligand Pharmaceuticals at Buy With $244 Price Target

MT Newswires Live
·
Mar 11

Ligand Pharmaceuticals Inc : Bofa Global Research Initiates Coverage With Buy Rating; Price Objective $244

THOMSON REUTERS
·
Mar 11

Ligand Pharmaceuticals Initiated at Buy by B of A Securities

Dow Jones
·
Mar 11